Our examination of the mutation landscape of LRGs and the correlation analysis with frequently mutated genes like APC, TP53, TTN, and KRAS (Fig. 6A, B) revealed that LRGs did not carry a substantial mutation burden but were strongly associated with pro-tumor pathways, such as “RTK-RAS,” “WNT,” “Hippo,” “PI3K,” “MYC,” and immune-related pathways like “TGF-β” (Fig. 6C). This evidence concerns the gene KRAS and neoplasm.